Sorivudine

From Wikipedia, the free encyclopedia
Sorivudine
Sorivudine.svg
Clinical data
Trade namesUsevir, Brovavir
Other namesBV-araU, Bromovinyl araU, 5-Bromovinyl-araU, 5-[(E)-2-bromoethenyl]-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
Routes of
administration
Oral
ATC code
  • none
Pharmacokinetic data
MetabolismViral thymidine kinase
ExcretionKidney
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC11H13BrN2O6
Molar mass349.137 g·mol−1
3D model (JSmol)
 ☒NcheckY (what is this?)  

Sorivudine (INN), is a nucleoside analogue antiviral drug, marketed under trade names such as Usevir (, Eisai) and Brovavir (BMS). It is used for the treatment of varicella zoster virus infections.[1]

Pharmacology[]

Feature[]

  • First-line[citation needed] treatment of herpes drug acyclovir was (Zovirax, Activir) from VZV strong activity of the virus.
  • Undergoes gastrointestinal absorption, absorption from the gastrointestinal tract after the most degrading without being excreted in urine.

Mechanism of action[]

  • Sorivudine is phosphorylated by thymidine kinase activity in the body and is absorbed into the virus's DNA instead of the correct nucleoside. It is a competitive inhibitor of DNA polymerase, so the viral DNA cannot be replicated and the virus cannot grow.

Microbiology[]

Sorivudine is active against most species in the herpesvirus family.

Interactions[]

Sorivudine interacts strongly and in some cases lethally with fluorouracil (5-FU), its prodrugs and related substances. This is based on the metabolite bromovinyluracil (BVU), which irreversibly inhibits the enzyme dihydropyrimidine dehydrogenase (DPD) which is necessary for inactivating 5-FU. The closely related drug brivudine has the same interaction.[2]

Bromovinyluracil (BVU)

References[]

  1. ^ Whitley RJ (1996). "Sorivudine: a potent inhibitor of varicella zoster virus replication". Advances in Experimental Medicine and Biology. 394: 41–4. doi:10.1007/978-1-4757-9209-6_5. PMID 8815706.
  2. ^ "UAW – Aus Fehlern lernen - Potenziell tödlich verlaufende Wechselwirkung zwischen Brivudin (Zostex) und 5-Fluoropyrimidinen" (PDF). Deutsches Ärzteblatt (in German). 103 (27). 7 July 2006.


Retrieved from ""